It shows the power of biotechnologies to solve great problems. Instead of soaking countries in chemicals and killing all insect - including beneficial - genetically altered mosquitos can eliminate mosquitos without harm to anything else.
Also: vaccine is estimated to be available about 10 years from now. Oxitec mosquito is right now only reasonable solution. Spray with chemicals will cause a lot of damage to other insects - namely big concern are bees. Brazil is already using Oxitec mosquito.
XON owns small biotech Oxitech which produces genetically altered mosquitos and are able to stop reproduction of mosquitos.
Thanks for the info. I noticed you always have info ahead of everybody else. Are you working in healthcare? You are exceptionally well informed.
It looks as if Big boys learned some positive news. Sure hope so.
Yes! You were so right with your warning. Cramer indicator worked again. Buy Juno at 56 --- and yesterday, at 44.63 ---don't buy, probably going lower.
I don't know, if stock will go higher after that, but somewhere here should be the bottom and time to buy.
CC went well
I cannot stand your posts and I never held ZIOP, just reading about all CAR-Ts and waiting for opportunity to buy some. I will join writing complains.
It's becoming crowded in immunotherapy. KITE and JUNO are considered leaders and they were overlooked. And they are about the same value. AZN will pay 5 B for Acerta.
There is sizable debate here why JUNO declined - and also KITE and other CAR-Ts and nobody is discussing article in Investor's Business Daily "KITE, Juno CAR-T Therapies Get FBR's Thumbs up" It appears in KITE headlines, but didn't show up in JUNO Headlines. Read it. There is sentence : "14 of 38 patients in Juno's previous JCAR015 relapsed...."
It cannot be good. If almost half of patients relapsed, it reduces success rate and changes perception what can be expected in area of CAR-T treatment.
This must have been known in well connected circles. Article appeared Dec. 8, but it takes time to prepare article like that - to collect data, so data were known some time before that. Cramer recommended buy JUNO Dec.1. He is former hedge fund manager, his loyalty is with that crowd and he many times recommended buy stock, that his buddies needed to unload. Just for reference: last winter, when JUNO was 40, caller asked if he should buy, Cramer answered "Not yet". Right !! Little dummy shouldn't buy at 40. That's price at which his buddies are buying. Little dummy should wait until stock goes to 56 and then buy - so that his buddies can unload.
I believe, that situation with relapse affected CAR-Ts.
They have success in pancreatic and lung cancer. Market watch today had very positive technical analysis in article "If a Santa Rally doesn't show up ......." It is on Summary page for ADRO.
Stock is in up trend. 50 Day Moving average is in distinctive uptrend.
What worries me is: Friday, DOW up 2.12%, S&P up 2.05%, Nas up 2.08%, IBB up 3.03 %, even beaten down some "new era" biotechs up - AGIO up 3,32%, BLUE up 6.42%.
On the other hand besides KITE and JUNO, BLCM down 4.28%, ZIOP down 6.23%. It's unsettling pattern. My guess is, that money managers with increasing number of players now see lower potential earnings for each of them.
In my view JUNO declined less than the others only because it had less run up than the others.
And another point to this line of thoughts - CLLS was up 3.6%. If reports are right and their cost per patient is $ 5000, it's jaw dropping and big game changer. Price of shares is all about earnings and those are now under pressures - more than one.
Anybody found anything about that Twitter gossip ? That can also be some shortseller.
There is a possibility, that cooperation of AMGN with MRK affected KITE. They will start immunotherapy trials in non - Hodgkin lymphoma, using CD - 19 receptor - it's KITE's territory. That would suggest, that AMGN as potential buyer of KITE is out. Instead, AMGN will be a competitor. That would explain sudden $ 20 drop.
Cooperation was announced today, but we all know, that well connected #$%$ always get head start. It's my take. What do you say, guys ?
IBB is up 1%. We just have bad luck to hold XON. KITE is also down 3%, but it had very big run up, so it's profit taking. XON just doesn't have buyers. There must be something fund managers do not like. I don't know what it is.
I am sure a lot of share yesterday were sold short.
Also - how I look at it. If treatment clears pancreatic cancer from body, infection, that can be cured well by antibiotic is not high price to pay. Infected patient didn't want to stop trial. Chemotherapy puts people through he ll, CAR-T therapies have severe sidefects - but they are acceptable, because they clear cancer from body and people get to live.